Elisabeth Ge de Vries

30PUBLICATIONS
179CO-AUTHORS
Molecular targetsMedical physicsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (30)

|Sep 10, 2026
Programmed death ligand 1 (PD-L1) PET/CT imaging to evaluate tumour saturation during atezolizumab treatment.

|May 08, 2026
Tri-specific Humabody CB307 Targeting CD137, Prostate-specific Membrane Antigen, and Human Serum Albumin Whole-body Biodistribution Measured with 89Zr-CB307 PET.

|Nov 25, 2025
Whole-body CD8+ T-cell PET imaging in patients with large B-cell lymphoma before and during CD19-directed CAR T-cell therapy: a phase 2 study.

Janneke W de Boer, Kylie Keijzer, Jaap A van Doesum

|Nov 10, 2025
Early [18F]FDG PET/CT Response after a Single Dose of Anti-EGFR Therapy as a Predictive Biomarker for Treatment Benefit in Patients with Advanced Colorectal Cancer.

Sophie L Gerritse, Erik J van Helden, Anne I J Arens

|Sep 10, 2025
Upfront whole blood transcriptional patterns in patients receiving immune checkpoint inhibitors associate with clinical outcome.

S Hone Lopez, S Loipfinger, A Bhattacharya

|Mar 17, 2025
A Phase I Dose Escalation and Cohort Expansion Study of CB307, a Trispecific Humabody against PSMA, CD137, and Albumin in Patients with PSMA-Positive Solid Tumors.

Johann S de Bono, Anja Williams, Ignacio Melero

Pageof 5

Frequent Collaborators

8 joint publications

Adrienne H Brouwers

7 joint publications

Marjolijn N Lub-de Hooge

7 joint publications

Rudolf S N Fehrmann

6 joint publications

Derk-Jan A de Groot